New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Ontario residents eligible for ODB and ...
At ATTD 2026, Dexcom (Nasdaq:DXCM) outlined a range of ways in which its continuous glucose monitors (CGMs) benefit people with diabetes.
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
The Dexcom 15-day G7 continuous glucose monitor (CGM) is accurate and safe for use up to 15.5 days in adults with diabetes. Currently under review by the US Food and Drug Administration, it is more ...
Diabetes technology innovators gathered last week for the Advanced Technologies and Treatments for Diabetes Conference (ATTD 2026).
Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results